LDHA and primary hyperoxaluria type 1: Wood et al.26 noted a significant rise in both liver and plasma pyruvate levels under nonexercise conditions in a PH1 mouse model treated with liver-specific siRNA targeted at LDHA. In contrast to these findings, Lai et al.20 noted that liver-specific siRNA-LDHA inhibition in mice did not result in significant elevations of plasma pyruvate under nonexercise conditions and during exercise.